CLASS ACTION UPDATE for ARLO, XRAY and WRCDF, WCAGY: Levi &

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
82
CLASS ACTION UPDATE for ARLO, XRAY and WRCDF, WCAGY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Arlo Technologies, Inc. (NYSE: ARLO) Class Period: Investors who purchased shares pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the August 3, 2018 Initial Public Offering Lead Plaintiff Deadline: March 25, 2019 Join the action: https://www.zlk.com/pslra-1/arlo-technologies...orm?wire=3

The filed complaint alleges that the Registration Statement made materially false and/or misleading statements and/or failed to disclose that: (i) there was a flaw and/or quality issue with Arlo’s newly designed battery for its Ultra camera systems; (ii) this flaw and/or quality issue with the Ultra battery could result in a shipping delay of Arlo’s Ultra product; (iii) such a shipping delay endangered Arlo’s chances of launching the Ultra product in time for the crucial holiday season; (iv) such a shipping delay would allow Arlo’s competitors to capitalize on the Ultra product’s missed launch, thereby increasing their own market share; (v) Arlo’s consumers had been experiencing battery drain issues and other battery-related issues in connection with recent firmware updates; (vi) because of the foregoing, Arlo’s fourth quarter 2018 results and consumer base would be negatively impacted; and (vii) as a result, Arlo’s Registration Statement was materially false and misleading at all relevant times.

To learn more about the Arlo Technologies, Inc. class action contact jlevi@levikorsinsky.com .

Dentsply Sirona, Inc. (NASDAQ: XRAY) Class Period: (i) all persons who purchased the common stock of Dentsply Sirona, Inc. (NASDAQ: XRAY) between February 20, 2014 and August 7, 2018; (ii) all Dentsply International Inc. shareholders who held shares as of the record date of December 2, 2015 and were entitled to vote with respect to the Acquisition at the January 11, 2016 special meeting of Dentsply International Inc. shareholders; and (iii) all persons who purchased or otherwise acquired the common stock of Dentsply International in exchange for their shares of common stock of Sirona in connection with the Acquisition Lead Plaintiff Deadline: February 19, 2019 Join the action: https://www.zlk.com/pslra-1/dentsply-sirona-i...orm?wire=3

According to the complaint, during the Class Period, Defendants attributed the Company’s financial performance to the Company’s “innovation,” “operational improvement efforts,” “new products,” and “continued investments in sales and marketing” and told investors that these factors helped the Company succeed despite the “highly competitive” market for its products. In reality, the Company’s financial results had been buoyed by an anticompetitive scheme among the Company’s three primary distributors that suppressed competition in the dental supply market and artificially inflated the price of dental supplies sold by Dentsply. Further, Defendants concealed that an exclusive distribution arrangement that Sirona had with one of its distributors, Patterson Companies, Inc. (“Patterson”), required Patterson to regularly make large minimum purchases regardless of demand and, as a result, by 2015, Patterson had been supplied with so much excess inventory that it could not be sold. This channel-stuffing rendered the Company’s reported sales, financial results and guidance materially false and misleading.  In addition, the Company represented that it reported its financial statements, including its goodwill, in accordance with generally accepted accounting principles, or GAAP. In fact, the Company’s reported goodwill was artificially inflated and not reported in accordance with GAAP because it did not reflect the financial impact of the anticompetitive scheme.

To learn more about the Dentsply Sirona, Inc. class action contact jlevi@levikorsinsky.com .

Wirecard AG (OTCMKTS: WRCDF, WCAGY) Class Period: April 7, 2016 - February 1, 2019 Lead Plaintiff Deadline: April 9, 2019 Join the action: https://www.zlk.com/pslra-1/wirecard-ag-loss-form?wire=3

Allegations: Wirecard AG made materially false and/or misleading statements and/or failed to disclose that: (1) for the period spanning from 2015 to 2018, a senior Wirecard executive in Singapore had been accused of forging and backdating contracts, including falsifying accounts and money laundering; (2) an external law firm commissioned to investigate Wirecard’s Singapore office had reportedly found evidence of “serious offences of forgery and/or of falsification of accounts”; (3) Wirecard had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (4) as a result, defendants’ statements about Wirecard’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Wirecard AG class action contact jlevi@levikorsinsky.com .

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 956

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 251

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 295

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 471

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 245

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 307

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 597

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading

Top 5 Most Recently Viewed Articles

Explore Consciousness at the CONTACT Modalities XPO Gathering

Updated Category News Views 271

CONTACT Modalities XPO: A Unique Gathering for Consciousness Exploration Prepare to embark on a transformative journey of self-discovery and exploration at the CONTACT Modalities XPO. This gathering promises to bring together passionate individuals eager to delve into consciousness studies through engaging sessions and workshops. The event will be held at the stunning...

Continue Reading
Green Thumb Industries Set to Unveil Q3 2025 Financial Overview

Updated Category News Views 266

Green Thumb Industries to Report Third Quarter Financial Results Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), a standout in the cannabis consumer packaged goods sector, is poised to unveil its financial performance for the third quarter of 2025. The eagerly anticipated announcement will occur after market hours on November 5, 2025. Known for its growth and...

Continue Reading
Boussard & Gavaudan Holding: Estimated NAV Update

Updated Category News Views 129

About Boussard & Gavaudan Holding Limited Boussard & Gavaudan Holding Limited aims to keep shareholders informed—plain and simple. The company provides timely updates on its estimated net asset values (NAVs) and on the performance of its Euro and Sterling share classes, so you can track what matters without guesswork. How the Estimated NAV Is Determined Each month, the...

Continue Reading
Booming Yacht Rental Market Set to Surpass $13 Billion Milestone

Updated Category News Views 93

The yacht rental market hit a turning point, projected to exceed $13.1 billion in value—back when those forecasts came out, traders were buzzing about it. The allure of luxury travel had folks flocking to yacht rentals like moths to a flame. Market Drivers: Luxury Demand or Overhyped? High-net-worth individuals fueled the demand for yacht rentals, as they sought...

Continue Reading
Hellenic Telecom Completes Share Repurchase, Strengthening Value

Updated Category News Views 156

Hellenic Telecom's Successful Share Buyback Program Hellenic Telecommunications Organization S.A. (ATH:HTO), widely recognized as OTE, has recently finished a significant week of share repurchasing. In a strategic move, the company acquired a total of 414,128 shares, investing approximately €6.16 million at an average price of €14.87 per share. Understanding the Share...

Continue Reading